

(c) removing non-adherent cells on the upper plate by changing medium.

2. (Canceled)

3. (Canceled)

4. (Previously presented) The method as claimed in claim 1, wherein the cell mixture comprises mammalian mesenchymal stem cells.

5. (Canceled)

6. (Previously presented) The method as claimed in claim 4, wherein the cell mixture comprises human mesenchymal stem cells.

7. (Canceled)

8. (Canceled)

9. (Previously presented) The method as claimed in claim 1, wherein the mesenchymal stem cells can differentiate into tissues comprising bone, adipose, or cartilage.

10. (Previously presented) The method as claimed in claim 1, wherein the mesenchymal stem cells are characterized by CD34-.

11. (Previously presented) The method as claimed in claim 1, wherein the culture medium is 10% fetal bovine serum-supplemented Dulbecco's modified Eagle's medium containing 1 g/L of glucose.

12. (Withdrawn) An isolated mesenchymal stem cell recovered by the method as claimed in claim 1, which has the capability of self-renewal and pluripotent differentiation.

13. (Withdrawn) The mesenchymal stem cell as claimed in claim 12, which can differentiate into tissue comprising bone, adipose, or cartilage.

14. (Withdrawn) The mesenchymal stem cell as claimed in claim 12, which is characterized by CD34-.

15. (Withdrawn) A composition comprising the mesenchymal stem cell as claimed in claim 12 and a culture medium, wherein the medium expands the mesenchymal stem cell.

16. (Withdrawn) The composition as claimed in claim 15, wherein the mesenchymal stem cell is characterized by CD34-.

17. (Withdrawn) The composition as claimed in claim 15, wherein the medium comprises DMEM-LG medium containing 10% fetal bovine serum.

18. (Withdrawn) A pharmaceutical composition comprising the mesenchymal stem cell as claimed in claim 12 and a pharmaceutically acceptable carrier, wherein the mesenchymal stem cell is present in an amount sufficient to serve as tissue replacement or gene therapy for tissue damaged by age, trauma, and disease.

19. (Withdrawn) A pharmaceutical composition as claimed in claim 18, wherein the mesenchymal stem cell can differentiate into tissues comprising bone, adipose, or cartilage.

20. (Withdrawn) A composition comprising as claimed in claim 18, wherein the mesenchymal stem cell is characterized by CD34-.

21-22. (Canceled)

23. (Canceled)

24-31. (Canceled)

32. (Withdrawn) the method as claimed in claim 1, further comprising, after step (b), a step of removing cells not adhered on the plate by changing a culture medium.

33. (Previously presented) The method as claimed in claim 1, wherein said pores are about 0.4 to 40 microns in diameter.

34. (Currently amended) ~~†~~The method as claimed in claim 1, wherein said the mesenchymal stem cell adhering material is plastic.

35. (Currently amended) ¶The method as claimed in claim 1, wherein said the mesenchymal stem cells cultured until confluence.

36. (Currently amended) ¶The method as claimed in claim 35, ~~said further comprising~~ recovering the mesenchymal stem cells cultured until confluence ~~for further re-plating to expand the mesenchymal stem cells.~~

37. (Currently amended) ¶The method as claimed in claim 36, wherein said recovering the mesenchymal stem cells from the upper plate is by using trypsin-EDTA.

38. (Currently amended) ¶The method as claimed in claim 36, ~~said further comprising~~ re-plating the cells to expand the mesenchymal stem cells at a density of  $4 \times 10^{3-4}$  /cm<sup>2</sup>.

39. (new) The method as claimed in claim 38, said re-plating the cells at a density of  $4 \times 10^{3-4}$  /cm<sup>2</sup>.

40 (new) The method as claimed in claim 1, wherein said upper plate has no intended surface roughness to expose a greater surface anchoring area to cells for attachment.